You searched for Antibody candidate - Page 54 of 69

News and Trends 4 Dec 2019

€48M Series B Fuels Immunotherapies for Cancer and Autoimmune Diseases

…use the money to fund the first phase I trial for its lead antibody immunotherapy for the treatment of various kinds of solid and liquid tumors. The trial is expected…

December 4, 2019 - 3 minutesmins - By Jonathan Smith

cancer treatments immuno oncology companies

News and Trends 23 Nov 2020

SynOx Joins Wave of Biotechs Attacking Solid Tumor ‘Comfort Zone’

…Celleron Therapeutics last week with a huge Series A round of €37M. The fledgling company is developing an antibody drug that Celleron licensed from Roche in August to treat a…

November 23, 2020 - 4 minutesmins - By Jonathan Smith

News and Trends 15 May 2020

Update: ADC Therapeutics’ IPO Hits Above Target with €215M

…large B-cell lymphoma, and ultimately bring the drug to the US market. Lausanne-based ADC Therapeutics specializes in the development of antibody-drug conjugates, in which an antibody is attached to a…

May 15, 2020 - 4 minutesmins - By Laura Cowen

News and Trends 1 Jun 2023

Sanofi drug reduces disease activity in relapsing MS

New data, being presented in a late-breaking session at the 2023 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting, demonstrate that frexalimab, Sanofi’s novel second-generation investigational anti-CD40L antibody, with a…

June 1, 2023 - 4 minutesmins - By Jim Cornall

cancer biotech killers deadliest oncology therapies immunooncology

News and Trends 19 Jan 2016

Top 8 Deadliest Cancers and their Potential Cures

…common in men (10.0%). Nanobiotix (France) is focused mainly on prostate cancer, however the NBTXR3 candidate is also being run in a phase I/II trial for colorectal cancer. Cetuximab (Erbitux)…

January 19, 2016 - 7 minutesmins - By Dani Bancroft

In Depth 30 Oct 2024

Could next-generation “switchable” CAR-T cells help improve the safety and efficacy of CAR-T therapies?

…different methods can be used, but generally speaking, it involves giving the patient a separate administration of another substance – whether that be an existing drug or a novel antibody,…

October 30, 2024 - 8 minutesmins - By Willow Shah-Neville

Best in Biotech 5 Dec 2017

Europe’s Brightest Stars: The 9 Best Biotech Companies of 2017

…candidates through the clinic. The antibody-drug conjugates combine monoclonal antibodies with the company’s specialized pyrrolobenzodiazepine (PBD) dimers as toxins. These molecules cross-link between DNA strands to block cell division and…

December 5, 2017 - 6 minutesmins - By Evelyn Warner

News and Trends 16 Feb 2021

Cancer Research UK Cuts Two Biotech Collaborations Amid Pandemic Squeeze

…trial, suggesting its candidate may at least partially boost the effects of the immunotherapy antibody rituximab in patients with drug-resistant non-Hodgkin’s lymphoma. The company reached its highest share price in…

February 16, 2021 - 4 minutesmins - By Anita Chakraverty

In Depth 14 Apr 2023

mRNA vaccines: a promising future

…vaccine that applies a similar mechanism whereby host cells are instructed to make copies of spike proteins to induce an immune response for antibody production. The first COVID 19 vaccine…

April 14, 2023 - 7 minutesmins - By Roohi Mariam Peter

News and Trends 19 Feb 2018

This Belgian Biotech Gives Us an Update on its Bulging Psoriasis Pipeline

…meeting. Belgian biopharma, UCB, develops medicines for people suffering from severe diseases of the immune or central nervous systems. The company is developing a number of candidates for moderate-to-severe chronic…

February 19, 2018 - 3 minutesmins - By Alex Dale

News and Trends 30 Jan 2017

‘Trojan Horse’ Shark Antibodies could beat the Blood Brain Barrier

Ossianix, partnered with Lundbeck, is developing shark antibodies that can help therapeutics cross the blood brain barrier. Ossianix develops shark-inspired antibody fragments, VNARs, with outstanding properties thanks to their small…

January 30, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 31 Aug 2022

Emactuzumab designated as an orphan medicinal product for TGCT in Europe

SynOx Therapeutics Limited says its novel monoclonal antibody, emactuzumab, in development for the treatment of tenosynovial giant cell tumor (TGCT) and other diseases, has been designated as an orphan medicinal…

August 31, 2022 - 4 minutesmins - By Jim Cornall

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Search Results for: Antibody candidate

€48M Series B Fuels Immunotherapies for Cancer and Autoimmune Diseases

SynOx Joins Wave of Biotechs Attacking Solid Tumor ‘Comfort Zone’

Update: ADC Therapeutics’ IPO Hits Above Target with €215M

Sanofi drug reduces disease activity in relapsing MS

Top 8 Deadliest Cancers and their Potential Cures

Could next-generation “switchable” CAR-T cells help improve the safety and efficacy of CAR-T therapies?

Europe’s Brightest Stars: The 9 Best Biotech Companies of 2017

Cancer Research UK Cuts Two Biotech Collaborations Amid Pandemic Squeeze

mRNA vaccines: a promising future

This Belgian Biotech Gives Us an Update on its Bulging Psoriasis Pipeline

‘Trojan Horse’ Shark Antibodies could beat the Blood Brain Barrier

Emactuzumab designated as an orphan medicinal product for TGCT in Europe

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!